Cargando…

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

Interleukin-2 (IL-2) treatment induces other cytokines such as tumour necrosis factor (TNF) TNF may mediate some of the anti-tumour activity of IL-2, but conversely, may contribute to its dose limiting toxicities. Cleaved extracellular domains of the p55 and the p75 TNF receptors (sTNF-R1 and R2) bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miles, D. W., Aderka, D., Engelmann, H., Wallach, D., Balkwill, F. R.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1992
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978036/ https://www.ncbi.nlm.nih.gov/pubmed/1333789

Ejemplares similares

Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.
por: Malik, S. T., et al.
Publicado: (1992)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis
por: Takasugi, Koji, et al.
Publicado: (2006)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Association of soluble interleukin‐2 receptor α and tumour necrosis factor receptor 1 with heart failure: The Multi‐Ethnic Study of Atherosclerosis
por: Bakhshi, Hooman, et al.
Publicado: (2020)

Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumours
por: Mielczarek-Palacz, Aleksandra, et al.
Publicado: (2012)

Soluble tumour necrosis factor receptor type II and survival in colorectal cancer
por: Babic, Ana, et al.
Publicado: (2016)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Evaluation of Tumour Necrosis Factor Alpha, Interleukin-2 Soluble Receptor, Nitric Oxide Metabolites, and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus
por: Pereira, Flávia Ozorio, et al.
Publicado: (2006)

Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF).
por: Leber, T. M., et al.
Publicado: (1998)

Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.
por: de Kossodo, S., et al.
Publicado: (1995)

Intratumoral induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine.
por: Minagawa, H., et al.
Publicado: (1990)

Serial measurement of the circulating levels of tumour necrosis factor and its soluble receptors 1 and 2 for monitoring leprosy patients during multidrug treatment
por: Costa, Rosane Dias, et al.
Publicado: (2013)

Mechanisms of tumor necrosis factor-α and interleukin-6 induction during human liver transplantation
por: Hamilton, Gerhard, et al.
Publicado: (1993)

Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma
por: Yoshida, N, et al.
Publicado: (2002)

Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4
por: Zekri, Abdel-Rahman N, et al.
Publicado: (2010)

Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis.
por: Kart, Levent, et al.
Publicado: (2003)

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
por: Yang, Nicole, et al.
Publicado: (2019)

IκBζ is a Key Regulator of Tumour Necrosis Factor-α and Interleukin-17A-mediated Induction of Interleukin-36η in Human Keratinocytes
por: OVESEN, Sofie Kaas, et al.
Publicado: (2021)

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
por: Trentin, L., et al.
Publicado: (1995)

Factors affecting the concentration of soluble tumour necrosis factor-α receptor type I in the blood serum of patients with localized scleroderma
por: Zbiciak-Nylec, Martyna, et al.
Publicado: (2020)

Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
por: Warzocha, K., et al.
Publicado: (1998)

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
Publicado: (1992)

Suppressive effect of TNF-α and IL-1 on alveolar fibroblast proliferation in sarcoidosis
por: Fireman, E., et al.
Publicado: (1992)

Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor.
por: Mahony, S. M., et al.
Publicado: (1988)

Tumour necrosis factor-alpha and interleukin-8 inhibit neutrophil migration in vitro and in vivo
por: Cunha, F. Q., et al.
Publicado: (1992)

Role of interleukin-1 and tumour necrosis factor in leukocyte recruitment to acute dermal inflammation
por: Issekutz, Andrew C., et al.
Publicado: (1992)

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis
por: Perry, M G, et al.
Publicado: (2009)

Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis
por: Kaczyński, Tomasz, et al.
Publicado: (2019)

Opioid receptor expression on neutrophils: effect of tumour necrosis factor alpha treatment
por: Schmidt, A, et al.
Publicado: (2007)

Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
por: Scotton, C, et al.
Publicado: (2001)

Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.
por: Pullyblank, A. M., et al.
Publicado: (1995)

The Role of Costimulatory Receptors of the Tumour Necrosis Factor Receptor Family in Atherosclerosis
por: Antunes, Ricardo F., et al.
Publicado: (2012)

Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha
por: Seow, W. Kim, et al.
Publicado: (1993)

Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells.
por: Jablonska, E
Publicado: (2002)

Tumour necrosis factor, interleukin-6 and interleukin-10 are possibly involved in Plasmodium vivax-associated thrombocytopaenia in southern Pakistani population
por: Raza, Afsheen, et al.
Publicado: (2014)

Assessment of Lipocalin 2, Clusterin, Soluble Tumor Necrosis Factor Receptor-1, Interleukin-6, Homocysteine, and Uric Acid Levels in Patients with Psoriasis
por: Ataseven, Arzu, et al.
Publicado: (2014)

Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor.
por: Malejczyk, J., et al.
Publicado: (1996)

Soluble tumour necrosis factor receptor I is a promising early indicator of complicated clinical outcome in patients following severe trauma
por: BINKOWSKA, ANETA M., et al.
Publicado: (2020)

Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
por: Lissoni, P., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_aqkn71ftrvo622t08754rjak67